Meeting
2020 Gastrointestinal Cancers Symposium
Benefit of oxaliplatin in stage III colon cancer according to IDEA risk groups: Analysis of MOSAIC and C-07 trials.
Authors
Ofer Margalit
Sheba Medical Center, Ramat Gan, Israel
Ofer Margalit , Ben Boursi , Manel Rakez , Thierry André , Greg Yothers , Norman Wolmark , Einat Shacham Shmueli , Aimery De Gramont
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Anal and Colorectal Cancer
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 118)
Abstract #
118
Poster Bd #
F4
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
PRODIGE 52-UCGI 29-CCTG/CO.27 (IROCAS): A multicenter, international, randomized phase III trial comparing adjuvant modified (m)FOLFIRINOX to mFOLFOX6 in patients with high-risk stage III (pT4 and/or N2) colon cancer (a UNICANCER GI-PRODIGE trial).
First Author: Jaafar Bennouna
Poster
2013 ASCO Annual Meeting
Effect of adding oxaliplatin to adjuvant 5-fluorouracil/leucovorin (5FU/LV) in patients with defective mismatch repair (dMMR) colon cancer stage II and III included in the MOSIAC study.
First Author: Jean-François Flejou
Poster
2019 Gastrointestinal Cancers Symposium
The effect of adjuvant chemotherapy for stage III colon cancer in elderly patients.
First Author: Naomi Hayashi
Poster
2014 Gastrointestinal Cancers Symposium
A retrospective analysis of the demographic profile and clinical outcomes of stage III colon cancer patients treated with adjuvant chemotherapy in a real-world perspective.
First Author: Praveen Ramakrishnan Geethakumari